Skip to main content

Table 5 Correlations of the expression of Smad4, Smad6 and Smad7 with clinicopathological parameters in 25 patients of pancreatic ductal adenocarcinoma

From: A study of Smad4, Smad6 and Smad7 in Surgically Resected Samples of Pancreatic Ductal Adenocarcinoma and Their Correlation with Clinicopathological Parameters and Patient Survival

Parameters Groups No.(n) Loss/low expression of Smad4 (%) P value
(2-tailed)
Loss/low expression of Smad 6 (%) P value Loss/low expression of Smad7(%) P value
Age < 50 5 4 (16%) 1.000 4 (16%) 0.244 4 (16%) 1.000
  ≥ 50 20 16 (40%)   10 (40%)   16 (64%)  
Sex Male 13 10 (40%) 0.704 7(28%) 0.830 10(40%) 0.704
  Female 12 10 (40%)   7 (28%)   10 (40%)  
Grade G1 13 11 (44%) 0.567 8 (32%) 0.580 9 (36%) 0.175
  G2 12 9 (36%)   6 (24%)   11 (44%)  
Stage I+II 10 7 (28%) 0.328 5 (20%) 0.639 8 (32%) 1.000
  III+IV 15 13 (52%)   9 (36%)   12 (48%)  
LN status Negative 19 15 (60%) 0.824 9 (36%) 0.132 15 (60%) 0.824
  Positive 6 5 (20%)   5 (20%)   5(20%)  
Tumor size < 3 cm 19 16 (64%) 0.370 11(44%) 0.747 17 (68%) 0.036*
  ≥3 cm 6 4 (16%)   3 (12%)   3 (12%)  
Margin status Positive 3 2 (8%) 0.558 1(4%) 0.420 1 (4%) 0.032*
  Negative 22 18 (72%)   13 (52%)   19 (76%)  
  1. *Significant values